Baird maintains an 'Outperform' on Amylin Pharmaceuticals (AMLN); Bydureon Approval Huge Positive, Removes Major Downside Risk

Baird maintains an 'Outperform' on Amylin Pharmaceuticals (NASDAQ: AMLN), price target raised from $15 to $17.

Baird analyst says, "While conviction built into our contrarian upgrade in November was highest to the mid-teens, and while we can appreciate a natural tension in the markets Monday, we believe reward/risk still skews favorably. The next potential positive in 2012--a successful o-US partnership transaction--seems more likely to us than the main potential negative--commercialization disappointment against the much lower "bar" there these days. We'd want continued exposure here."

For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.

Shares of Amylin Pharmaceuticals closed at $12.14 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold